Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of TTNP opened at $6.12 on Wednesday. Titan Pharmaceuticals has a twelve month low of $5.00 and a twelve month high of $13.97. The firm’s fifty day simple moving average is $6.73 and its 200-day simple moving average is $6.82.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) EPS for the quarter. Titan Pharmaceuticals had a negative return on equity of 99.96% and a negative net margin of 2,014.71%.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.